Granules India Share Price
822.65+0.00 (+2.68%)
+51.17% past 1 Year
Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.
Price Analysis
About
Stock Analysis (SWOT)
QVT
Peer Stocks
1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
LAURUSLABSNSE
ZYDUSLIFENSE
DRREDDYNSE
CIPLANSE
MANKINDNSE
AUROPHARMANSE
LUPINNSE
GRANULESNSE
Granules India Share Price
822.65+0.00 (+2.68%)
+51.17% past 1 Year
Financial overview
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
CAGR%
Sales
Profits
Returns
ROE
| 10Y | 5Y | 3Y | TTM |
|---|---|---|---|
| 15% | 11% | 6% | 20% |
| 17% | 2% | 5% | 19% |
| 24% | 22% | 31% | 51% |
| 18% | 16% | 14% | 14% |
Peer Comparison
Symbol
SUNPHARMA
DIVISLAB
TORNTPHARM
LAURUSLABS
ZYDUSLIFE
DRREDDY
CIPLA
MANKIND
AUROPHARMA
LUPIN
GRANULES
| Price | M.Cap (₹) | PE Ratio | EPS (₹) | EV/EBITDA | Annual PAT |
|---|---|---|---|---|---|
| 1,908.7 | ₹456593 Cr | 41.64 | 8.29 | 58.23 | ₹11479 Cr |
| 11,120.5 | ₹296741 Cr | 88.24 | 42.53 | 146.01 | ₹2568 Cr |
| 4,626.2 | ₹175578 Cr | 82.66 | 14.04 | 106.21 | ₹2163 Cr |
| 2,304.4 | ₹124380 Cr | 92.83 | 8.17 | 33.94 | ₹889 Cr |
| 1,235 | ₹119700 Cr | 28.64 | 9.27 | 62.23 | ₹5040 Cr |
| 1,396.5 | ₹116771 Cr | 41.71 | 11.08 | 59.16 | ₹4196 Cr |
| 1,421.8 | ₹114397 Cr | 39.49 | 10.86 | 52.6 | ₹3879 Cr |
| 2,636.7 | ₹108641 Cr | 48.44 | 17.23 | 76.25 | ₹1913 Cr |
| 1,803.3 | ₹103971 Cr | 26.06 | 19.57 | 103.44 | ₹3505 Cr |
| 2,002.6 | ₹91413 Cr | 17.56 | 25.26 | 150.99 | ₹5333 Cr |
| 797.3 | ₹21942 Cr | 30.75 | 6.67 | 37.85 | ₹595 Cr |
Profit & Loss
Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | Sep 2020 | Jun 2020 | Mar 2020 | Dec 2019 | Sep 2019 | Jun 2019 | Mar 2019 | Dec 2018 | Sep 2018 | Jun 2018 | Mar 2018 | Dec 2017 | Sep 2017 | Jun 2017 | Mar 2017 | Dec 2016 | Sep 2016 | Jun 2016 | Mar 2016 | Dec 2015 | Sep 2015 | Jun 2015 | Mar 2015 | Dec 2014 | Sep 2014 | Jun 2014 | Mar 2014 | Dec 2013 | Sep 2013 | Jun 2013 | Mar 2013 | Dec 2012 | Sep 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ₹1560 Cr | ₹1477 Cr | ₹1471 Cr | ₹1388 Cr | ₹1297 Cr | ₹1210 Cr | ₹1197 Cr | ₹1138 Cr | ₹967 Cr | ₹1180 Cr | ₹1176 Cr | ₹1156 Cr | ₹1189 Cr | ₹986 Cr | ₹1196 Cr | ₹1146 Cr | ₹1151 Cr | ₹1020 Cr | ₹1030 Cr | ₹997 Cr | ₹888 Cr | ₹850 Cr | ₹799 Cr | ₹845 Cr | ₹858 Cr | ₹736 Cr | ₹600 Cr | ₹704 Cr | ₹700 Cr | ₹595 Cr | ₹613 Cr | ₹632 Cr | ₹581 Cr | ₹453 Cr | ₹504 Cr | ₹411 Cr | ₹393 Cr | ₹385 Cr | ₹362 Cr | ₹359 Cr | ₹364 Cr | ₹350 Cr | ₹376 Cr | ₹325 Cr | ₹353 Cr | ₹323 Cr | ₹355 Cr | ₹320 Cr | ₹308 Cr | ₹311 Cr | ₹317 Cr | ₹284 Cr | ₹266 Cr | ₹228 Cr | ₹204 Cr | ₹195 Cr | ₹175 Cr |
| ₹11 Cr | ₹2 Cr | ₹9 Cr | -₹4 Cr | -₹1 Cr | ₹16 Cr | ₹2 Cr | ₹6 Cr | ₹3 Cr | ₹2 Cr | ₹2 Cr | ₹65 L | ₹2 Cr | ₹35 L | ₹3 Cr | ₹95 L | ₹5 Cr | ₹5 Cr | ₹4 Cr | ₹5 Cr | ₹4 Cr | ₹8 Cr | ₹3 Cr | ₹16 Cr | ₹3 Cr | ₹6 Cr | ₹23 Cr | ₹4 Cr | ₹9 Cr | ₹2 Cr | ₹2 Cr | ₹6 Cr | ₹4 Cr | ₹15 Cr | ₹10 Cr | ₹86 L | ₹7 Cr | ₹1 Cr | ₹1 Cr | ₹4 Cr | ₹4 Cr | ₹3 Cr | ₹1 Cr | ₹1 Cr | ₹97 L | ₹1 Cr | ₹2 Cr | ₹87 L | ₹54 L | ₹42 L | ₹1 Cr | ₹48 L | ₹50 L | ₹2 Cr | ₹1 Cr | ₹53 L | ₹24 L |
| ₹1571 Cr | ₹1479 Cr | ₹1479 Cr | ₹1384 Cr | ₹1296 Cr | ₹1226 Cr | ₹1199 Cr | ₹1143 Cr | ₹970 Cr | ₹1182 Cr | ₹1178 Cr | ₹1156 Cr | ₹1191 Cr | ₹986 Cr | ₹1199 Cr | ₹1147 Cr | ₹1156 Cr | ₹1024 Cr | ₹1034 Cr | ₹1002 Cr | ₹893 Cr | ₹857 Cr | ₹803 Cr | ₹861 Cr | ₹861 Cr | ₹741 Cr | ₹622 Cr | ₹707 Cr | ₹708 Cr | ₹597 Cr | ₹615 Cr | ₹638 Cr | ₹585 Cr | ₹468 Cr | ₹513 Cr | ₹412 Cr | ₹399 Cr | ₹386 Cr | ₹363 Cr | ₹364 Cr | ₹368 Cr | ₹353 Cr | ₹377 Cr | ₹326 Cr | ₹354 Cr | ₹324 Cr | ₹357 Cr | ₹321 Cr | ₹308 Cr | ₹311 Cr | ₹319 Cr | ₹285 Cr | ₹267 Cr | ₹230 Cr | ₹205 Cr | ₹196 Cr | ₹176 Cr |
| ₹1306 Cr | ₹1218 Cr | ₹1200 Cr | ₹1153 Cr | ₹1091 Cr | ₹1032 Cr | ₹1009 Cr | ₹964 Cr | ₹816 Cr | ₹973 Cr | ₹973 Cr | ₹957 Cr | ₹1029 Cr | ₹898 Cr | ₹1016 Cr | ₹963 Cr | ₹952 Cr | ₹851 Cr | ₹877 Cr | ₹862 Cr | ₹777 Cr | ₹688 Cr | ₹642 Cr | ₹670 Cr | ₹638 Cr | ₹586 Cr | ₹539 Cr | ₹580 Cr | ₹586 Cr | ₹505 Cr | ₹543 Cr | ₹545 Cr | ₹507 Cr | ₹405 Cr | ₹481 Cr | ₹356 Cr | ₹334 Cr | ₹326 Cr | ₹303 Cr | ₹302 Cr | ₹308 Cr | ₹298 Cr | ₹312 Cr | ₹274 Cr | ₹299 Cr | ₹274 Cr | ₹320 Cr | ₹279 Cr | ₹268 Cr | ₹270 Cr | ₹278 Cr | ₹246 Cr | ₹239 Cr | ₹204 Cr | ₹183 Cr | ₹182 Cr | ₹160 Cr |
| ₹348 Cr | ₹341 Cr | ₹361 Cr | ₹304 Cr | ₹277 Cr | ₹263 Cr | ₹254 Cr | ₹236 Cr | ₹207 Cr | ₹261 Cr | ₹258 Cr | ₹251 Cr | ₹215 Cr | ₹137 Cr | ₹231 Cr | ₹232 Cr | ₹248 Cr | ₹216 Cr | ₹197 Cr | ₹179 Cr | ₹156 Cr | ₹209 Cr | ₹205 Cr | ₹228 Cr | ₹260 Cr | ₹189 Cr | ₹122 Cr | ₹167 Cr | ₹152 Cr | ₹120 Cr | ₹99 Cr | ₹119 Cr | ₹105 Cr | ₹87 Cr | ₹53 Cr | ₹75 Cr | ₹84 Cr | ₹77 Cr | ₹79 Cr | ₹81 Cr | ₹78 Cr | ₹72 Cr | ₹80 Cr | ₹67 Cr | ₹69 Cr | ₹64 Cr | ₹52 Cr | ₹55 Cr | ₹53 Cr | ₹53 Cr | ₹52 Cr | ₹46 Cr | ₹34 Cr | ₹32 Cr | ₹29 Cr | ₹19 Cr | ₹21 Cr |
| ₹21 Cr | ₹21 Cr | ₹33 Cr | ₹29 Cr | ₹29 Cr | ₹24 Cr | ₹24 Cr | ₹27 Cr | ₹26 Cr | ₹27 Cr | ₹29 Cr | ₹29 Cr | ₹26 Cr | ₹22 Cr | ₹19 Cr | ₹17 Cr | ₹13 Cr | ₹7 Cr | ₹6 Cr | ₹5 Cr | ₹5 Cr | ₹7 Cr | ₹7 Cr | ₹7 Cr | ₹6 Cr | ₹6 Cr | ₹7 Cr | ₹7 Cr | ₹7 Cr | ₹7 Cr | ₹7 Cr | ₹7 Cr | ₹8 Cr | ₹7 Cr | ₹6 Cr | ₹8 Cr | ₹10 Cr | ₹8 Cr | ₹8 Cr | ₹8 Cr | ₹8 Cr | ₹8 Cr | ₹9 Cr | ₹10 Cr | ₹9 Cr | ₹8 Cr | ₹8 Cr | ₹9 Cr | ₹8 Cr | ₹7 Cr | ₹8 Cr | ₹5 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹5 Cr | ₹4 Cr |
| ₹243 Cr | ₹240 Cr | ₹262 Cr | ₹202 Cr | ₹176 Cr | ₹145 Cr | ₹198 Cr | ₹153 Cr | ₹128 Cr | ₹181 Cr | ₹176 Cr | ₹170 Cr | ₹136 Cr | ₹65 Cr | ₹164 Cr | ₹167 Cr | ₹190 Cr | ₹166 Cr | ₹150 Cr | ₹135 Cr | ₹110 Cr | ₹163 Cr | ₹154 Cr | ₹184 Cr | ₹217 Cr | ₹149 Cr | ₹137 Cr | ₹89 Cr | ₹115 Cr | ₹85 Cr | ₹65 Cr | ₹85 Cr | ₹71 Cr | ₹56 Cr | ₹27 Cr | ₹47 Cr | ₹55 Cr | ₹52 Cr | ₹53 Cr | ₹54 Cr | ₹51 Cr | ₹47 Cr | ₹56 Cr | ₹42 Cr | ₹46 Cr | ₹42 Cr | ₹29 Cr | ₹33 Cr | ₹32 Cr | ₹34 Cr | ₹33 Cr | ₹34 Cr | ₹23 Cr | ₹22 Cr | ₹18 Cr | ₹9 Cr | ₹11 Cr |
| ₹182 Cr | ₹180 Cr | ₹202 Cr | ₹150 Cr | ₹131 Cr | ₹113 Cr | ₹152 Cr | ₹118 Cr | ₹97 Cr | ₹135 Cr | ₹130 Cr | ₹126 Cr | ₹102 Cr | ₹48 Cr | ₹120 Cr | ₹124 Cr | ₹145 Cr | ₹128 Cr | ₹111 Cr | ₹101 Cr | ₹81 Cr | ₹120 Cr | ₹128 Cr | ₹147 Cr | ₹164 Cr | ₹111 Cr | ₹92 Cr | ₹64 Cr | ₹96 Cr | ₹58 Cr | ₹45 Cr | ₹58 Cr | ₹47 Cr | ₹37 Cr | ₹17 Cr | ₹30 Cr | ₹35 Cr | ₹34 Cr | ₹36 Cr | ₹36 Cr | ₹36 Cr | ₹32 Cr | ₹36 Cr | ₹29 Cr | ₹32 Cr | ₹29 Cr | ₹22 Cr | ₹24 Cr | ₹22 Cr | ₹23 Cr | ₹24 Cr | ₹22 Cr | ₹15 Cr | ₹15 Cr | ₹12 Cr | ₹6 Cr | ₹8 Cr |
Balance Sheet
Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Share Warrants & Outstandings
Total Reserves
Reserve excluding Revaluation Reserve
Revaluation reserve
Shareholder's Funds
Minority Interest
Secured Loans
Unsecured Loans
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Capital Work in Progress
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Currents Investments
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Miscellaneous Expenses not written off
Total Assets
Book Value
Adjusted Book Value
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | Mar 2009 | Jun 2008 | Jun 2007 | Jun 2006 | Jun 2005 | Jun 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| ₹25 Cr | ₹24 Cr | ₹24 Cr | ₹24 Cr | ₹25 Cr | ₹25 Cr | ₹25 Cr | ₹25 Cr | ₹25 Cr | ₹23 Cr | ₹22 Cr | ₹20 Cr | ₹20 Cr | ₹20 Cr | ₹20 Cr | ₹20 Cr | ₹22 Cr | ₹22 Cr | ₹20 Cr | ₹20 Cr | ₹12 Cr | ₹12 Cr | ₹8 Cr |
| ₹366 Cr | ₹14 Cr | ₹18 Cr | ₹18 Cr | ₹17 Cr | ₹22 Cr | ₹18 Cr | ₹11 Cr | ₹5 Cr | ₹2 Cr | ₹29 Cr | ₹0 | ₹25 L | ₹32 L | ₹0 | ₹0 | ₹0 | ₹0 | ₹2 Cr | ₹2 Cr | ₹1 Cr | ₹0 | ₹0 |
| ₹4695 Cr | ₹3678 Cr | ₹3183 Cr | ₹2793 Cr | ₹2545 Cr | ₹2126 Cr | ₹1800 Cr | ₹1493 Cr | ₹1273 Cr | ₹878 Cr | ₹611 Cr | ₹411 Cr | ₹335 Cr | ₹254 Cr | ₹225 Cr | ₹200 Cr | ₹181 Cr | ₹153 Cr | ₹152 Cr | ₹146 Cr | ₹66 Cr | ₹60 Cr | ₹21 Cr |
| ₹4695 Cr | ₹3678 Cr | ₹3183 Cr | ₹2793 Cr | ₹2545 Cr | ₹2126 Cr | ₹1800 Cr | ₹1493 Cr | ₹1273 Cr | ₹878 Cr | ₹611 Cr | ₹411 Cr | ₹335 Cr | ₹254 Cr | ₹225 Cr | ₹200 Cr | ₹181 Cr | ₹153 Cr | ₹152 Cr | ₹146 Cr | ₹66 Cr | ₹60 Cr | ₹20 Cr |
| ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹30 L | ₹57 L |
| ₹5085 Cr | ₹3716 Cr | ₹3226 Cr | ₹2835 Cr | ₹2587 Cr | ₹2173 Cr | ₹1844 Cr | ₹1529 Cr | ₹1304 Cr | ₹904 Cr | ₹662 Cr | ₹431 Cr | ₹356 Cr | ₹275 Cr | ₹245 Cr | ₹220 Cr | ₹202 Cr | ₹175 Cr | ₹174 Cr | ₹167 Cr | ₹80 Cr | ₹73 Cr | ₹29 Cr |
| ₹0 | ₹0 | ₹0 | ₹0 | ₹56 L | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹297 Cr | ₹312 Cr | ₹69 Cr | ₹149 Cr | ₹234 Cr | ₹334 Cr | ₹415 Cr | ₹479 Cr | ₹433 Cr | ₹124 Cr | ₹184 Cr | ₹303 Cr | ₹296 Cr | ₹175 Cr | ₹87 Cr | ₹37 Cr | ₹136 Cr | ₹166 Cr | ₹134 Cr | ₹116 Cr | ₹116 Cr | ₹88 Cr | ₹62 Cr |
| ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹7 Cr | ₹0 | ₹0 | ₹34 L | ₹55 L | ₹62 L | ₹13 Cr | ₹65 L | ₹75 L | ₹75 L | ₹11 Cr | ₹17 Cr | ₹11 Cr | ₹18 Cr | ₹11 Cr | ₹6 Cr | ₹8 Cr |
| -₹27 Cr | -₹36 Cr | -₹14 Cr | ₹6 Cr | ₹13 Cr | ₹32 L | ₹43 Cr | ₹61 Cr | ₹47 Cr | ₹56 Cr | ₹57 Cr | ₹49 Cr | ₹30 Cr | ₹24 Cr | ₹23 Cr | ₹20 Cr | ₹17 Cr | ₹12 Cr | ₹10 Cr | ₹8 Cr | ₹6 Cr | ₹4 Cr | ₹3 Cr |
| ₹161 Cr | ₹159 Cr | ₹83 Cr | ₹71 Cr | ₹8 Cr | ₹7 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹48 Cr | ₹32 Cr | ₹38 Cr | ₹29 Cr | ₹28 Cr | ₹25 Cr | ₹22 Cr | ₹13 Cr | ₹8 Cr | ₹7 Cr | ₹6 Cr | ₹4 Cr | ₹4 Cr | ₹2 Cr | ₹2 Cr | ₹1 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹479 Cr | ₹466 Cr | ₹176 Cr | ₹255 Cr | ₹283 Cr | ₹366 Cr | ₹486 Cr | ₹553 Cr | ₹488 Cr | ₹188 Cr | ₹247 Cr | ₹357 Cr | ₹344 Cr | ₹202 Cr | ₹113 Cr | ₹59 Cr | ₹164 Cr | ₹196 Cr | ₹155 Cr | ₹142 Cr | ₹133 Cr | ₹98 Cr | ₹73 Cr |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| ₹673 Cr | ₹726 Cr | ₹750 Cr | ₹782 Cr | ₹639 Cr | ₹541 Cr | ₹357 Cr | ₹323 Cr | ₹274 Cr | ₹216 Cr | ₹181 Cr | ₹188 Cr | ₹136 Cr | ₹92 Cr | ₹76 Cr | ₹52 Cr | ₹38 Cr | ₹28 Cr | ₹24 Cr | ₹17 Cr | ₹23 Cr | ₹16 Cr | ₹13 Cr |
| ₹336 Cr | ₹305 Cr | ₹261 Cr | ₹193 Cr | ₹201 Cr | ₹194 Cr | ₹153 Cr | ₹114 Cr | ₹70 Cr | ₹93 Cr | ₹79 Cr | ₹89 Cr | ₹48 Cr | ₹24 Cr | ₹31 Cr | ₹19 Cr | ₹9 Cr | ₹3 Cr | ₹16 Cr | ₹1 Cr | ₹71 L | ₹31 L | ₹91 L |
| ₹1025 Cr | ₹923 Cr | ₹1054 Cr | ₹811 Cr | ₹766 Cr | ₹409 Cr | ₹372 Cr | ₹454 Cr | ₹525 Cr | ₹474 Cr | ₹393 Cr | ₹125 Cr | ₹101 Cr | ₹85 Cr | ₹102 Cr | ₹83 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹58 Cr | ₹50 Cr | ₹17 Cr | ₹27 Cr | ₹37 Cr | ₹29 Cr | ₹12 Cr | ₹5 Cr | ₹9 Cr | ₹4 Cr | ₹2 Cr | ₹13 Cr | ₹8 Cr | ₹5 Cr | ₹5 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹4 Cr | ₹3 Cr | ₹2 Cr | ₹2 Cr | ₹3 Cr |
| ₹2092 Cr | ₹2003 Cr | ₹2082 Cr | ₹1814 Cr | ₹1642 Cr | ₹1173 Cr | ₹893 Cr | ₹896 Cr | ₹878 Cr | ₹787 Cr | ₹655 Cr | ₹415 Cr | ₹293 Cr | ₹206 Cr | ₹214 Cr | ₹157 Cr | ₹49 Cr | ₹34 Cr | ₹43 Cr | ₹21 Cr | ₹26 Cr | ₹18 Cr | ₹18 Cr |
| ₹7656 Cr | ₹6185 Cr | ₹5484 Cr | ₹4903 Cr | ₹4512 Cr | ₹3713 Cr | ₹3223 Cr | ₹2979 Cr | ₹2670 Cr | ₹1879 Cr | ₹1563 Cr | ₹1203 Cr | ₹992 Cr | ₹683 Cr | ₹571 Cr | ₹436 Cr | ₹415 Cr | ₹405 Cr | ₹372 Cr | ₹330 Cr | ₹238 Cr | ₹189 Cr | ₹119 Cr |
| ₹93 L | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹99 L | ₹99 L | ₹153 Cr | ₹147 Cr | ₹154 Cr | ₹133 Cr | ₹140 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹103 Cr | ₹101 Cr | ₹108 Cr | ₹79 Cr | ₹99 Cr | ₹63 Cr | ₹24 Cr |
| ₹1338 Cr | ₹1286 Cr | ₹1223 Cr | ₹1059 Cr | ₹1093 Cr | ₹838 Cr | ₹892 Cr | ₹991 Cr | ₹978 Cr | ₹657 Cr | ₹641 Cr | ₹482 Cr | ₹442 Cr | ₹270 Cr | ₹204 Cr | ₹137 Cr | ₹147 Cr | ₹183 Cr | ₹145 Cr | ₹134 Cr | ₹127 Cr | ₹94 Cr | ₹70 Cr |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| ₹4988 Cr | ₹3882 Cr | ₹3352 Cr | ₹2981 Cr | ₹2462 Cr | ₹2145 Cr | ₹1875 Cr | ₹1473 Cr | ₹1200 Cr | ₹984 Cr | ₹823 Cr | ₹844 Cr | ₹654 Cr | ₹387 Cr | ₹354 Cr | ₹323 Cr | ₹303 Cr | ₹291 Cr | ₹197 Cr | ₹168 Cr | ₹142 Cr | ₹71 Cr | ₹68 Cr |
| ₹1738 Cr | ₹1456 Cr | ₹1256 Cr | ₹1070 Cr | ₹921 Cr | ₹813 Cr | ₹671 Cr | ₹529 Cr | ₹423 Cr | ₹339 Cr | ₹263 Cr | ₹227 Cr | ₹171 Cr | ₹124 Cr | ₹104 Cr | ₹84 Cr | ₹66 Cr | ₹48 Cr | ₹41 Cr | ₹31 Cr | ₹23 Cr | ₹17 Cr | ₹14 Cr |
| ₹3250 Cr | ₹2426 Cr | ₹2096 Cr | ₹1911 Cr | ₹1541 Cr | ₹1332 Cr | ₹1204 Cr | ₹944 Cr | ₹777 Cr | ₹644 Cr | ₹560 Cr | ₹617 Cr | ₹482 Cr | ₹263 Cr | ₹250 Cr | ₹239 Cr | ₹237 Cr | ₹243 Cr | ₹156 Cr | ₹137 Cr | ₹119 Cr | ₹53 Cr | ₹54 Cr |
| ₹406 Cr | ₹437 Cr | ₹260 Cr | ₹228 Cr | ₹312 Cr | ₹185 Cr | ₹148 Cr | ₹324 Cr | ₹290 Cr | ₹130 Cr | ₹77 Cr | ₹62 Cr | ₹125 Cr | ₹109 Cr | ₹29 Cr | ₹7 Cr | ₹2 Cr | ₹2 Cr | ₹93 Cr | ₹71 Cr | ₹24 Cr | ₹37 Cr | ₹5 Cr |
| ₹84 L | ₹22 Cr | ₹22 Cr | ₹21 Cr | ₹20 Cr | ₹19 Cr | ₹19 Cr | ₹210 Cr | ₹157 Cr | ₹108 Cr | ₹70 Cr | ₹19 L | ₹19 L | ₹19 L | ₹19 L | ₹30 L | ₹30 L | ₹29 L | ₹29 L | ₹29 L | ₹31 L | ₹20 L | ₹28 L |
| ₹84 L | ₹22 Cr | ₹22 Cr | ₹21 Cr | ₹20 Cr | ₹19 Cr | ₹19 Cr | ₹210 Cr | ₹157 Cr | ₹108 Cr | ₹70 Cr | ₹19 L | ₹19 L | ₹19 L | ₹19 L | ₹30 L | ₹30 L | ₹29 L | ₹29 L | ₹29 L | ₹31 L | ₹20 L | ₹28 L |
| ₹226 Cr | ₹180 Cr | ₹190 Cr | ₹157 Cr | ₹89 Cr | ₹126 Cr | ₹77 Cr | ₹46 Cr | ₹36 Cr | ₹31 Cr | ₹38 Cr | ₹21 Cr | ₹5 Cr | ₹16 Cr | ₹30 Cr | ₹11 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹2 Cr | ₹1 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹1 Cr | ₹98 L | ₹1 Cr | ₹36 L | ₹12 L | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹3888 Cr | ₹3069 Cr | ₹2579 Cr | ₹2329 Cr | ₹2007 Cr | ₹1716 Cr | ₹1594 Cr | ₹1696 Cr | ₹1484 Cr | ₹1051 Cr | ₹745 Cr | ₹701 Cr | ₹613 Cr | ₹390 Cr | ₹311 Cr | ₹257 Cr | ₹240 Cr | ₹245 Cr | ₹249 Cr | ₹209 Cr | ₹143 Cr | ₹90 Cr | ₹60 Cr |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹9 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹1673 Cr | ₹1343 Cr | ₹1301 Cr | ₹1149 Cr | ₹979 Cr | ₹782 Cr | ₹438 Cr | ₹384 Cr | ₹280 Cr | ₹269 Cr | ₹254 Cr | ₹225 Cr | ₹174 Cr | ₹136 Cr | ₹110 Cr | ₹75 Cr | ₹69 Cr | ₹60 Cr | ₹53 Cr | ₹30 Cr | ₹35 Cr | ₹27 Cr | ₹21 Cr |
| ₹909 Cr | ₹942 Cr | ₹986 Cr | ₹949 Cr | ₹925 Cr | ₹765 Cr | ₹662 Cr | ₹674 Cr | ₹628 Cr | ₹418 Cr | ₹375 Cr | ₹137 Cr | ₹111 Cr | ₹71 Cr | ₹95 Cr | ₹72 Cr | ₹66 Cr | ₹63 Cr | ₹38 Cr | ₹37 Cr | ₹43 Cr | ₹36 Cr | ₹24 Cr |
| ₹949 Cr | ₹596 Cr | ₹386 Cr | ₹313 Cr | ₹409 Cr | ₹271 Cr | ₹284 Cr | ₹89 Cr | ₹116 Cr | ₹50 Cr | ₹130 Cr | ₹65 Cr | ₹42 Cr | ₹42 Cr | ₹32 Cr | ₹12 Cr | ₹13 Cr | ₹13 Cr | ₹11 Cr | ₹36 Cr | ₹6 Cr | ₹23 Cr | ₹4 Cr |
| ₹73 Cr | ₹54 Cr | ₹46 Cr | ₹49 Cr | ₹62 Cr | ₹51 Cr | ₹43 Cr | ₹37 Cr | ₹49 Cr | ₹40 Cr | ₹10 Cr | ₹33 Cr | ₹11 Cr | ₹7 Cr | ₹5 Cr | ₹5 Cr | ₹4 Cr | ₹5 Cr | ₹6 Cr | ₹6 Cr | ₹5 Cr | ₹5 Cr | ₹5 Cr |
| ₹163 Cr | ₹180 Cr | ₹186 Cr | ₹114 Cr | ₹130 Cr | ₹128 Cr | ₹92 Cr | ₹98 Cr | ₹114 Cr | ₹52 Cr | ₹49 Cr | ₹41 Cr | ₹39 Cr | ₹23 Cr | ₹19 Cr | ₹15 Cr | ₹22 Cr | ₹17 Cr | ₹14 Cr | ₹11 Cr | ₹5 Cr | ₹5 Cr | ₹4 Cr |
| ₹3768 Cr | ₹3115 Cr | ₹2905 Cr | ₹2574 Cr | ₹2505 Cr | ₹1997 Cr | ₹1519 Cr | ₹1282 Cr | ₹1187 Cr | ₹828 Cr | ₹818 Cr | ₹500 Cr | ₹377 Cr | ₹289 Cr | ₹260 Cr | ₹179 Cr | ₹174 Cr | ₹157 Cr | ₹121 Cr | ₹120 Cr | ₹94 Cr | ₹96 Cr | ₹58 Cr |
| ₹1676 Cr | ₹1112 Cr | ₹823 Cr | ₹761 Cr | ₹863 Cr | ₹824 Cr | ₹625 Cr | ₹386 Cr | ₹309 Cr | ₹41 Cr | ₹163 Cr | ₹85 Cr | ₹84 Cr | ₹83 Cr | ₹47 Cr | ₹22 Cr | ₹125 Cr | ₹123 Cr | ₹77 Cr | ₹99 Cr | ₹68 Cr | ₹78 Cr | ₹41 Cr |
| ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹2 Cr | ₹3 Cr | ₹4 Cr | ₹28 L | ₹0 | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹97 L |
| ₹7656 Cr | ₹6185 Cr | ₹5484 Cr | ₹4903 Cr | ₹4512 Cr | ₹3713 Cr | ₹3223 Cr | ₹2979 Cr | ₹2670 Cr | ₹1879 Cr | ₹1563 Cr | ₹1203 Cr | ₹992 Cr | ₹683 Cr | ₹571 Cr | ₹436 Cr | ₹415 Cr | ₹405 Cr | ₹372 Cr | ₹330 Cr | ₹238 Cr | ₹189 Cr | ₹119 Cr |
| ₹190 | ₹153 | ₹132 | ₹116 | ₹104 | ₹87 | ₹72 | ₹60 | ₹51 | ₹39 | ₹29 | ₹21 | ₹174 | ₹135 | ₹122 | ₹110 | ₹99 | ₹85 | ₹85 | ₹82 | ₹62 | ₹57 | ₹33 |
| ₹190 | ₹153 | ₹132 | ₹116 | ₹104 | ₹87 | ₹72 | ₹60 | ₹51 | ₹39 | ₹29 | ₹21 | ₹17 | ₹13 | ₹12 | ₹11 | ₹10 | ₹9 | ₹8 | ₹8 | ₹6 | ₹6 | ₹3 |
Cash Flow
Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Cash & Cash Equivalent on Amalgamation / Take over / Merger
Effect of Foreign Exchange Fluctuations
Closing Cash & Cash Equivalent
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | Mar 2009 | Jun 2008 | Jun 2007 | Jun 2006 | Jun 2005 | Jun 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ₹785 Cr | ₹660 Cr | ₹547 Cr | ₹687 Cr | ₹558 Cr | ₹704 Cr | ₹426 Cr | ₹277 Cr | ₹180 Cr | ₹205 Cr | ₹186 Cr | ₹128 Cr | ₹112 Cr | ₹46 Cr | ₹43 Cr | ₹27 Cr | ₹38 Cr | ₹7 Cr | ₹13 Cr | ₹11 Cr | ₹9 Cr | ₹7 Cr | ₹7 Cr |
| ₹390 Cr | ₹344 Cr | ₹329 Cr | ₹238 Cr | ₹176 Cr | ₹194 Cr | ₹157 Cr | ₹150 Cr | ₹107 Cr | ₹95 Cr | ₹93 Cr | ₹85 Cr | ₹50 Cr | ₹41 Cr | ₹38 Cr | ₹33 Cr | ₹25 Cr | ₹24 Cr | ₹23 Cr | ₹19 Cr | ₹14 Cr | ₹11 Cr | ₹11 Cr |
| -₹142 Cr | ₹6 Cr | -₹246 Cr | -₹10 Cr | -₹257 Cr | -₹275 Cr | ₹13 Cr | -₹76 Cr | -₹230 Cr | -₹52 Cr | -₹80 Cr | -₹31 Cr | -₹31 Cr | ₹15 Cr | -₹44 Cr | -₹6 Cr | ₹3 Cr | -₹43 Cr | -₹3 Cr | -₹21 Cr | -₹9 Cr | -₹19 Cr | -₹20 Cr |
| ₹1033 Cr | ₹1010 Cr | ₹630 Cr | ₹915 Cr | ₹477 Cr | ₹624 Cr | ₹595 Cr | ₹351 Cr | ₹57 Cr | ₹248 Cr | ₹199 Cr | ₹182 Cr | ₹132 Cr | ₹102 Cr | ₹37 Cr | ₹54 Cr | ₹66 Cr | -₹12 Cr | ₹32 Cr | ₹9 Cr | ₹15 Cr | -₹56 L | -₹2 Cr |
| ₹793 Cr | ₹867 Cr | ₹439 Cr | ₹739 Cr | ₹332 Cr | ₹432 Cr | ₹476 Cr | ₹262 Cr | -₹65 L | ₹188 Cr | ₹151 Cr | ₹150 Cr | ₹108 Cr | ₹91 Cr | ₹26 Cr | ₹49 Cr | ₹60 Cr | -₹12 Cr | ₹18 Cr | -₹4 Cr | ₹4 Cr | -₹10 Cr | -₹12 Cr |
| -₹773 Cr | -₹691 Cr | -₹360 Cr | -₹191 Cr | -₹380 Cr | -₹277 Cr | -₹161 Cr | -₹270 Cr | -₹462 Cr | -₹326 Cr | -₹162 Cr | -₹146 Cr | -₹255 Cr | -₹128 Cr | -₹54 Cr | -₹25 Cr | -₹13 Cr | -₹9 Cr | -₹54 Cr | -₹74 Cr | -₹55 Cr | -₹34 Cr | -₹24 Cr |
| ₹379 Cr | -₹93 Cr | ₹8 Cr | -₹440 Cr | ₹190 Cr | -₹299 Cr | -₹213 Cr | -₹17 Cr | ₹529 Cr | ₹56 Cr | ₹86 Cr | ₹19 Cr | ₹147 Cr | ₹46 Cr | ₹49 Cr | -₹25 Cr | -₹46 Cr | ₹23 Cr | ₹11 Cr | ₹109 Cr | ₹35 Cr | ₹64 Cr | ₹38 Cr |
| ₹399 Cr | ₹83 Cr | ₹87 Cr | ₹107 Cr | ₹142 Cr | -₹144 Cr | ₹103 Cr | -₹25 Cr | ₹66 Cr | -₹82 Cr | ₹75 Cr | ₹24 Cr | ₹4 L | ₹10 Cr | ₹20 Cr | -₹1 Cr | ₹64 L | ₹2 Cr | -₹26 Cr | ₹30 Cr | -₹17 Cr | ₹19 Cr | ₹2 Cr |
| ₹466 Cr | ₹381 Cr | ₹292 Cr | ₹185 Cr | ₹42 Cr | ₹186 Cr | ₹83 Cr | ₹108 Cr | ₹42 Cr | ₹124 Cr | ₹55 Cr | ₹42 Cr | ₹42 Cr | ₹32 Cr | ₹12 Cr | ₹13 Cr | ₹13 Cr | ₹11 Cr | ₹36 Cr | ₹6 Cr | ₹23 Cr | ₹4 Cr | ₹2 Cr |
| ₹2 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹12 Cr | ₹2 Cr | ₹3 Cr | -₹25 L | ₹94 L | -₹12 L | ₹20 L | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹880 Cr | ₹466 Cr | ₹381 Cr | ₹292 Cr | ₹185 Cr | ₹42 Cr | ₹186 Cr | ₹83 Cr | ₹108 Cr | ₹42 Cr | ₹130 Cr | ₹65 Cr | ₹42 Cr | ₹42 Cr | ₹32 Cr | ₹12 Cr | ₹13 Cr | ₹13 Cr | ₹11 Cr | ₹36 Cr | ₹6 Cr | ₹23 Cr | ₹4 Cr |
Fundamental Ratios
Consolidated
Standalone

No results found
Granules India Share Price
822.65+0.00 (+2.68%)
+51.17% past 1 Year
Technical meters
Oscillators
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 3
Bearish signals: 2 out of 9 oscillators
RSI
52.22Neutral
STOCH %K
69.89Neutral
MACD Level(12,26)
-4.61Sell
Ultimate Oscillator
52.56Buy
Aroon Oscillator
-72.00Sell
BOP
0.71Buy
CCI
19.36Neutral
Williams %R
-30.11Neutral
Momentum
1.95Buy
Moving averages
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 8
Bearish signals: 1 out of 9 moving averages
EMA 9
809.80Buy
SMA 9
809.77Buy
EMA 21
812.63Buy
SMA 21
812.33Buy
EMA 50
821.94Buy
SMA 50
830.76Sell
EMA 200
761.19Buy
SMA 200
755.77Buy
WMA 20
809.48Buy
Pivot
Pivot
Classic
Resistance 5
888.25
Resistance 4
866.20
Resistance 3
844.15
Resistance 2
822.10
Resistance 1
811.65
Pivot
800.05
Support 1
789.60
Support 2
778.00
Support 3
755.95
Support 4
733.90
Support 5
711.85
High & lows
1 Day
1 Week
1 Month
3 Months
6 Months
Year to Date
1 Year
3 Years
5 Years
10 Years
All Time
Granules India Share Price
822.65+0.00 (+2.68%)
+51.17% past 1 Year
Shareholding summary
Shareholding Pattern
Quarterly
Yearly
Name
Promoters
FII
DII - Others
DII - MFs
Retail & Others
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|---|
| 37.39% | 38.02% | 38.02% | 38.82% | 38.82% | 38.82% |
| 20.25% | 17.50% | 15.31% | 13.55% | 14.09% | 13.24% |
| 11.06% | 12.66% | 14.16% | 12.12% | 11.37% | 11.28% |
| 4.26% | 3.45% | 2.85% | 5.35% | 6.54% | 12.24% |
| 27.04% | 28.37% | 29.66% | 30.16% | 29.18% | 24.42% |
Bulk & block deals
Name
Saumik Ketankumar Doshi
Saumik Ketankumar Doshi
Bnp Paribas Financial Markets
Sundaram Mutual Fund
Kotak Mahindra Life Insurance Company Limited
Krishna Prasad Chigurupati
Myraa Varun Raheja
Smallcap World Fund Inc
Jagdish Naresh Master
Krishna Prasad Chigurupati
| Deal Date | Action | Deal Value | Deal Price | Qty Traded | Deal Type | %Stake Traded | Exchange |
|---|---|---|---|---|---|---|---|
| 12 Nov 2026 | Purchase | 109.51 Cr | ₹823.54 | 13.30 L | Bulk | 0.536648 | NSE |
| 12 Nov 2026 | Sell | 85.36 Cr | ₹821.12 | 10.40 L | Bulk | 0.419502 | NSE |
| 11 Sep 2026 | Purchase | 115 Cr | ₹872.50 | 13.18 L | Bulk | 0.531908 | NSE |
| 11 Sep 2026 | Purchase | 50 Cr | ₹872.50 | 5.73 L | Block | 0.231264 | NSE |
| 11 Sep 2026 | Purchase | 100.71 Cr | ₹872.50 | 11.54 L | Block | 0.465831 | NSE |
| 11 Sep 2026 | Sell | 1,160 Cr | ₹872.50 | 1.33 Cr | Bulk | 5.365333 | NSE |
| 11 Sep 2026 | Purchase | 60 Cr | ₹872.50 | 6.88 L | Block | 0.277517 | NSE |
| 11 Sep 2026 | Purchase | 303.11 Cr | ₹872.50 | 34.74 L | Bulk | 1.401987 | NSE |
| 11 Sep 2026 | Purchase | 26.18 Cr | ₹872.50 | 3 L | Block | 0.121067 | NSE |
| 11 Sep 2026 | Sell | 348.64 Cr | ₹892.84 | 39.05 L | Bulk | 1.575835 | NSE |
Insider trading & SAST
Client name
Priyanka Chigurupati
Pragnya Chigurupati
Harsha Chigurupati
Pragnya Chigurupati
Chigurupati Uma Devi
Chigurupati Uma Devi
Priyanka Chigurupati
Harsha Chigurupati
Life Insurance Corporation Of India
Life Insurance Corporation Of India
| Reported on | Client category | Action | %Stake traded | Holding % post deal | Deal value | Deal price | Qty traded | Deal period | Deal mode | Post transaction holding | Insider/SAST | Regulation type | Security type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | Promoter Group | Acquisition | 0.013797 | 0.01 | 50 L | ₹146.25 | 34.19 K | 23 Feb 2026 | Preferential Offer | 34,188 | Insider Trading | — | Warrant |
| 23 Oct 2026 | Promoter Group | Acquisition | 0.013797 | 0.01 | 50 L | ₹146.25 | 34.19 K | 23 Feb 2026 | Preferential Offer | 34,188 | Insider Trading | — | Warrant |
| 23 Oct 2026 | Promoter Group | Acquisition | 0.013797 | 0.01 | 50 L | ₹146.25 | 34.19 K | 23 Feb 2026 | Preferential Offer | 34,188 | Insider Trading | — | Warrant |
| 23 Oct 2026 | Promoter Group | Acquisition | 0.013797 | 0.69 | 1.50 Cr | ₹438.75 | 34.19 K | 16 Sep 2026 | Preferential Offer | 18,76,223 | Insider Trading | — | Equity |
| 23 Oct 2026 | Promoter Group | Acquisition | 10.040619 | 12.51 | 1,091.63 Cr | ₹438.75 | 2.49 Cr | 16 Sep 2026 | Preferential Offer | 3,41,21,103 | Insider Trading | — | Equity |
| 23 Oct 2026 | Promoter Group | Acquisition | 10.040619 | 9.12 | 363.88 Cr | ₹146.25 | 2.49 Cr | 23 Feb 2026 | Preferential Offer | 2,48,80,342 | Insider Trading | — | Warrant |
| 23 Oct 2026 | Promoter Group | Acquisition | 0.013797 | 0.68 | 1.50 Cr | ₹438.75 | 34.19 K | 16 Sep 2026 | Preferential Offer | 18,52,871 | Insider Trading | — | Equity |
| 23 Oct 2026 | Promoter Group | Acquisition | 0.013797 | 0.01 | 1.50 Cr | ₹438.75 | 34.19 K | 16 Sep 2026 | Preferential Offer | 34,188 | Insider Trading | — | Equity |
| 27 Aug 2026 | Other | Disposal | 2.1 | 2.91 | 0 | — | 49.56 L | 27 Feb 2025 - 03 Aug 2026 | Market | 72,26,446 | SAST | 29(2) | — |
| 25 Mar 2025 | Other | Acquisition | 0.03 | 5.02 | 0 | — | 79 K | 27 Feb 2025 | Market | 1,21,82,570 | SAST | 29(1) | — |
Granules India Share Price
822.65+0.00 (+2.68%)
+51.17% past 1 Year
Granules India is a vertically integrated pharmaceutical company with a presence across the entire value chain - from Active Pharmaceutical Ingredients (APIs) and Pharmaceutical Formulation Intermediates (PFIs) to Finished Dosages
Corporate Actions
Date
Type
Details
Company details
Granules India Share Price
822.65+0.00 (+2.68%)
+51.17% past 1 Year
Corporate filings & documents
Announcements
Annual reports
Concalls & investor presentations
Granules India Share Price
822.65+0.00 (+2.68%)
+51.17% past 1 Year
News
1 of 20
Stock NewsGRANULES6 Nov 2026
NULL
Granules India informs about change in corporate office address
Stock NewsGRANULES6 Nov 2026
NULL
Granules India Gagillapur Facility Receives Eleven USFDA Observations
Stock NewsGRANULES6 Nov 2026
Granules India Limited's finished dosage facility at Gagillapur, Hyderabad, received eleven observations in a Form FDA 483 following a USFDA current Good Manufacturing Practice inspection conducted from October 19 to October 30, 2026. The observations relate to investigations, change control, process and equipment qualification, visual inspection controls and documentation practices. The inspection was the first at the facility since the USFDA Warning Letter issued on February 26, 2025.
The company stated that none of the observations involved data integrity or cross-contamination and that manufacturing and product distribution from the site remain unaffected. Granules India plans to submit a comprehensive response to the USFDA within 15 business days. The findings may require corrective and preventive actions and could increase compliance-related costs, while the absence of data integrity and cross-contamination observations reduces immediate supply disruption risk. The regulatory outcome and adequacy of the company's remediation will remain relevant for future US-market operations.
The development is negative for near-term regulatory sentiment, although no quantified earnings impact or production interruption was disclosed.
Granules India reports Profit after tax of 108.52 Crores, in the September 2026 quarter
ResultGRANULES2 Nov 2026
NULL
Granules Reports Higher Second Quarter EBITDA With Stable Operating Margin
ResultGRANULES2 Nov 2026
Granules reported second-quarter EBITDA of Rs 340 crores, rising from Rs 278 crores year on year. EBITDA margin improved to 21.64% from 21.45% in the corresponding quarter. Revenue and PAT figures, along with sequential comparisons and street expectations, were not provided in the available update.
The stronger EBITDA and marginally improved operating margin indicate improved operating performance during the quarter. The result is specific to Granules India, a pharmaceutical company operating across APIs, pharmaceutical formulation intermediates, and finished dosages. No management commentary or market reaction was provided.
Granules India reports strong second quarter consolidated profit growth
ResultGRANULES2 Nov 2026
Granules India reported consolidated Q2 net profit of Rs 182 crores, compared with Rs 130 crores in the corresponding quarter a year earlier, marking a 40 percent year-on-year increase. Revenue and EBITDA figures were not provided in the available result update and are therefore not included. The reported profit growth indicates improved quarterly earnings performance, although sequential growth, operating margin, net margin, and market reaction could not be assessed from the available information.
Granules India Reports Strong Second Quarter Revenue Growth
ResultGRANULES2 Nov 2026
Granules India reported second-quarter revenue of Rs 1,560.00 crores, rising 20.28 percent year on year from Rs 1,297.00 crores. EBITDA and PAT figures were not provided in the available update, so operating margin, net margin, and profit growth cannot be assessed. The revenue increase indicates stronger quarterly sales performance, while sequential growth, management commentary, market reaction, and comparison with street expectations were not disclosed. Granules India operates in the pharmaceuticals and drugs sector, with business exposure spanning APIs, pharmaceutical formulation intermediates, and finished dosages.
US FDA Begins Inspection Of Granules India Gagillapur Facility
Stock NewsGRANULES19 Oct 2026
The US FDA has commenced an inspection of Granules India’s Gagillapur facility in Telangana. The inspection is a routine regulatory assessment of the company’s manufacturing operations and may cover compliance with current good manufacturing practices, quality systems, documentation, production processes and data integrity. No inspection observations, regulatory findings, warning letter, import alert or remediation requirement have been disclosed in the available information. The facility is a significant manufacturing site for Granules India’s pharmaceutical operations, including active pharmaceutical ingredients, pharmaceutical formulation intermediates and finished dosage products. The inspection outcome could influence regulatory continuity, product supplies and future approvals in the US market, although the immediate financial impact cannot be quantified without findings or management commentary. No corporate action, earnings change, capital expenditure quantum or same-day stock price impact has been provided.
Granules India Seeks Sole First To File Status For Ruxolitinib Tablets
Stock NewsGRANULES7 Oct 2026
Granules India has submitted a Paragraph IV certification linked to its Abbreviated New Drug Application for Ruxolitinib Extended Release Tablets, targeting patents listed with the US Food and Drug Administration. Based on the timing and status of its application, the company believes it may qualify for sole first to file status.
If the US Food and Drug Administration confirms the status and all statutory requirements are met, Granules India may become eligible for 180 days of generic drug exclusivity under US law. The application remains subject to regulatory review, and the filing does not represent product approval or confirmation of exclusivity. Potential exclusivity could support future US generic revenue and market share, although the timing and commercial benefit remain dependent on regulatory and legal outcomes.
Granules India Targets Sole First To File Opportunity For Ruxolitinib
Stock NewsGRANULES7 Oct 2026
Granules India has submitted a Paragraph IV certification with its Abbreviated New Drug Application for Ruxolitinib Extended Release Tablets against applicable patents listed with the US FDA. Based on the timing and status of its application, the company believes it may qualify for sole first to file status, subject to US FDA review and determination.
If confirmed and all statutory and regulatory requirements are met, the opportunity could provide up to 180 days of generic drug exclusivity in the US. Chairman and Managing Director Krishna Prasad Chigurupati said first to file opportunities are an important part of the company strategy to build a more differentiated and higher value product portfolio in the US. The announcement does not disclose expected sales, investment, approval timelines, or earnings impact.
Granules India Plans Rs 2,000 Crore Organic Growth Investment
Stock NewsGRANULES6 Oct 2026
Granules India plans to invest Rs 2,000 crores in organic growth over the next 3 to 4 years. The company also expects its peptide contract development and manufacturing organisation division to generate revenue of approximately $5.00 crores within 3 years and $10.00 crores within 5 years.
The planned investment is aimed at expanding the company’s pharmaceutical manufacturing and higher-value peptide CDMO capabilities. Successful execution could support long-term revenue growth, strengthen market share, and improve business diversification, although the investment may increase capital requirements during the expansion period.
Granules India co-promoter group fully pays Rs 1,093 crore for warrants
Stock NewsGRANULES15 Sept 2026
Granules India has announced that its co-promoter group has completed payment of Rs 1,093 crore towards a preferential issue of warrants. This preferential allotment involves 2.49 crore warrants, which are now ready for conversion into equity shares of the company. The completion of the payment by the co-promoter group indicates strong financial commitment from the promoters and supports the company’s capital-raising plans through the preferential route. The sizeable quantum of Rs 1,093 crore reflects a meaningful infusion of growth capital into Granules India, which can be deployed towards expanding manufacturing capacities, funding research and development, or strengthening the balance sheet, depending on the company’s stated strategic priorities. The conversion of 2.49 crore warrants into equity shares, once executed, will likely lead to equity base expansion and may have implications for earnings per share, promoter holding, and overall capital structure. For existing shareholders, the preferential issue to the co-promoter group can be interpreted as a signal of confidence in the medium- to long-term prospects of Granules India’s business, particularly in its core pharmaceutical formulations and bulk drugs operations. From a market perspective, the completion of such a large preferential payment by promoters tends to be viewed as a supportive corporate development, although the eventual impact on per-share metrics will depend on how effectively the raised capital is deployed and the timing of warrant conversion. In the near term, the news is likely to keep investor focus on the company’s growth pipeline, margin profile and return ratios as the newly raised funds begin to be utilised.
Granules India co-promoter trims stake via 1.72 crore share sale
Stock NewsGRANULES11 Sept 2026
Granules India has seen a significant change in its shareholding structure following a sizeable secondary market transaction by the promoter group. Co-promoter Krishna Prasad has sold 1.72 crore equity shares of the company, leading to a material reduction in the collective holding of the promoter group. Post this sale, the promoter group stake has declined from 38.02% to 31.08%. This quantum of stake sale indicates a strategic rebalancing of holdings by the co-promoter and introduces a larger free float for the stock, which may improve liquidity and broaden institutional and retail participation over time. However, it also represents a notable reduction in promoter skin in the game, which the market typically monitors closely for any signals on long-term commitment or capital allocation preferences.
The transaction does not, by itself, alter the company’s operating fundamentals, as it is an offload of shares by an existing co-promoter rather than a primary issuance or capital-raising exercise. There is no indication in the given context of any concurrent change in management control, board composition, or strategic direction of Granules India. The company continues to operate in the pharmaceuticals space, and its business performance will remain driven by factors such as product portfolio, capacity utilisation, regulatory approvals, input costs, and demand trends in key markets. From a corporate governance and ownership standpoint, the reduction of the promoter group stake from above one-third to near one-third of the equity base may incrementally enhance the voice of institutional and public shareholders in shareholder decisions that require ordinary resolutions. Market participants are likely to watch subsequent shareholding pattern disclosures and trading volumes to assess whether this sale leads to further stake changes, new strategic investors, or shifts in the shareholder base. In the absence of information on price reaction on the day, the immediate market impact of the announcement cannot be precisely calibrated, but such large promoter stake sales generally attract heightened attention from both short-term traders and long-term investors.
Granules India NSE block trade of Rs 253 crores at Rs 894.30
Block DealGRANULES11 Sept 2026
Granules India Ltd. witnessed a sizeable block trade in the NSE, indicating notable institutional-level activity in the stock. The reported deal size is approximately Rs 253.00 crores, executed for about 2,829,004 equity shares of the company. The negotiated price for this transaction is Rs 894.30 per share, reflecting the level at which a large buyer and seller were willing to transact outside the regular market order book. Such block trades are typically facilitated between institutional investors, funds, or large stakeholders, and are executed in a separate window to minimise impact on the regular market order flow.
Based on the recent market data for Granules India, the stock has been trading in the Rs 890–915 band on the NSE in the latest sessions, with closing and live prices around Rs 899–913, placing the block trade price of Rs 894.30 very close to the prevailing market levels. This suggests the deal was struck broadly in line with the current market price, rather than at a steep premium or discount, implying a transfer of a meaningful stake without an aggressive valuation signal. The exact identities of the buyer and seller, their classification as promoters, FIIs, DIIs, or other strategic investors, and the precise percentage stake change are not disclosed in the provided context and therefore cannot be quantified here. However, given the share count relative to the company’s market capitalisation and typical trading volumes, the transaction is material at the stock level but not large enough to be considered index-moving or a major macro event. Post-deal follow-through in terms of stock price movement, change in ownership pattern, or any associated strategic announcements is not available in the current information set, and thus no inference is drawn on subsequent price behaviour or corporate intent.
Granules India sees Rs 1160 crore NSE block trade at pre-open price
Block DealGRANULES11 Sept 2026
Granules India witnessed a sizable block trade on the NSE in the pre-open session, involving approximately 1.33 crore shares transacted at a price of Rs 872.5 per share. The total deal value is around Rs 1160 crore, indicating meaningful institutional interest or portfolio rebalancing, though specific buyer and seller identities have not been disclosed in the available context. Based on the latest available data, Granules India’s stock has been trading in the high Rs 800 range, with recent spot prices around Rs 892–899 on leading market data platforms, suggesting that the block price of Rs 872.5 is at a modest discount to the prevailing market price, which is typical for large negotiated transactions where counterparties seek execution certainty and liquidity.
The share count of roughly 13295129 shares is substantial relative to the free float, pointing to a meaningful shift in ownership between large shareholders, such as institutional investors or funds, although the exact stakeholder category is not specified. Recent ownership data shows that key domestic institutions like Life Insurance Corporation of India and SBI Life Insurance Company Limited hold notable stakes in Granules India, underscoring that the counter is already on the radar of long-term institutional investors. However, in the absence of a confirmed regulatory filing or detailed disclosure on whether promoters, strategic investors, or financial institutions are on the buy or sell side in this specific block, any inference on promoter stake change or strategic intent would be speculative and therefore is not included.
Given the size of the transaction, the block deal is a significant liquidity event for Granules India and may influence near-term trading dynamics, including volumes and order-book depth. Yet, without verifiable information on follow-through price action post-deal or explicit commentary from the company or exchanges, the impact on the medium-term fundamental outlook remains indeterminate within the constraints of available, validated data. The summary therefore focuses strictly on the confirmed quantum, price level, and relative positioning versus recent trading ranges, avoiding unstated assumptions on future performance or sentiment trajectory.
Granules gains comfort as FDA clears corrective actions at Gagillapur unit
Stock NewsGRANULES27 Jul 2026
Granules India has reported a significant regulatory positive, indicating that the US FDA has no concerns regarding the corrective actions implemented at its Gagillapur manufacturing facility. This marks an important milestone in the company’s compliance journey, as seven of its eight manufacturing sites now have clean inspection reports from the regulator. A clean FDA status is critical for uninterrupted exports to the US market, supports sustained product approvals, and reduces the risk of supply disruptions or remediation expenses. The update suggests that previously identified issues at the Gagillapur unit have been addressed to the satisfaction of the US FDA, thereby lowering regulatory overhang on the stock and operations.
With the majority of Granules’ facilities now enjoying a compliant status, the company is better positioned to leverage its existing ANDA portfolio and to pursue new filings without significant regulatory impediments. This improvement in the compliance profile is likely to support medium-term earnings visibility through more stable US revenues and potential volume growth from key molecules. Although no specific details on incremental capacity, revenue contribution, or capex related to Gagillapur are disclosed in the available context, the overall regulatory clean-up reduces operational risk and may aid margin stability by avoiding additional remediation costs. The development is particularly relevant for investors tracking regulatory risk in Indian pharma exporters, as it signals enhanced quality systems and governance within Granules’ manufacturing network.
There is no immediate information on stock price movement, corporate actions such as buyback, dividend, or M&A, or any change in leverage profile linked directly to this event. However, from a fundamental standpoint, improved FDA compliance across seven of eight units strengthens Granules’ platform for future growth in regulated markets and supports its competitive positioning among Indian peers supplying to the US.
Granules India Q1 revenue rises to Rs 1,500 crore versus Rs 1,200 crore year on year
ResultGRANULES21 Jul 2026
Granules India reported Q1 revenue of Rs 1,500.00 crore, compared with Rs 1,200.00 crore in the same quarter last year, indicating year on year growth in top line.
The context provided only includes revenue, so EBITDA, PAT, and margin data are not available and are therefore omitted. No street estimate, management guidance, or stock price reaction was provided in the input.
Based on the reported revenue increase alone, the update reflects an operational improvement for the quarter, but the overall financial quality of the result cannot be assessed from the available details.
Granules India Q1 PAT surges 63 percent, beats FY27 growth guidance
ResultGRANULES21 Jul 2026
Granules India has reported a strong set of numbers for the first quarter, with profit after tax (PAT) growing by 63 percent, significantly ahead of the company’s longer-term guidance for FY27, where management has indicated an expected PAT growth range of 15 to 20 percent. The sharp outperformance in quarterly PAT growth versus the medium-term guidance points to robust operating performance and better-than-expected profitability in the near term. While the detailed revenue and EBITDA figures for the quarter are not provided in the available context, the magnitude of PAT acceleration suggests healthy topline trends combined with either operating leverage, better product mix, or improved cost efficiencies. Net margin expansion is implicitly indicated by PAT growth far exceeding the guided trajectory for earnings, and this is consistent with recent commentary that margins are expected to improve from current levels over the medium term.
The contrast between the current quarter’s 63 percent PAT growth and the FY27 guidance band of 15 to 20 percent implies that the company may be front-loading earnings growth, benefiting from recent capacity additions, favourable demand for formulations and APIs, and possibly better utilization levels. From an investor perspective, such a strong quarterly outcome versus conservative medium-term guidance typically signals prudent management communication and leaves room for positive surprises if operational momentum sustains. The absence of specific street expectations, consensus forecasts, and stock price reaction data in the given context limits a more granular comparison with market estimates. However, on a standalone basis, the earnings print can be considered materially strong relative to the guidance benchmark and indicates improving profitability trends for Granules India.
Granules India Q1 EBITDA rises strongly year-on-year with margin expansion
ResultGRANULES21 Jul 2026
Granules India reported a strong improvement in operating performance for the latest reported Q1 period, driven by robust growth in earnings before interest, tax, depreciation and amortisation (EBITDA). Q1 EBITDA came in at Rs 340 crores compared with Rs 247 crores in the same quarter last year, reflecting a healthy year-on-year increase in operating profit in absolute terms. This jump in EBITDA indicates stronger operating efficiency and better profitability from the company’s core pharmaceutical operations versus the year-ago period.
EBITDA margin for the quarter improved to 22.94 percent from 20.4 percent on a year-on-year basis, marking a notable expansion in operating margin. The improvement of more than 250 basis points suggests better cost management, an improved product mix, or enhanced capacity utilisation, resulting in higher profitability per rupee of revenue. The margin expansion also indicates that the company has been able to defend or improve pricing and absorb input and operating costs more effectively compared with the previous year’s first quarter.
While the detailed revenue and profit after tax (PAT) numbers are not provided in the given context, the sharp increase in EBITDA and meaningful margin expansion position this Q1 result as operationally strong for Granules India within the Indian pharmaceutical space. From an earnings quality standpoint, higher EBITDA and margins without any referenced one-off items imply an underlying improvement in the business performance. In the absence of information on consensus expectations, management commentary, or stock price reaction, this update primarily highlights a positive trend in operating profitability, which is an important metric for investors tracking Granules India on NSE/BSE.
Granules India Q1 consolidated net profit jumps sharply on YoY basis
ResultGRANULES21 Jul 2026
Granules India reported a strong improvement in profitability for the latest reported first quarter, with consolidated net profit rising to around Rs 180 crores compared with Rs 110 crores in the same quarter last year on a year-on-year basis. This sharp increase in profit indicates a significant expansion in earnings, reflecting better operational performance, improved product mix, or efficiency gains across its formulations and active pharmaceutical ingredients businesses. While detailed revenue, EBITDA and margin data are not provided in the context, the magnitude of profit growth suggests that either operating margins or net margins have improved meaningfully over the comparable period, or that non-operating items have been favorable relative to the previous year.
In the absence of explicit revenue and EBITDA numbers, the focus remains on the pronounced rise in profit after tax, which is a key indicator watched by investors for assessing earnings momentum. The year-on-year comparison from Rs 110 crores to Rs 180 crores underscores strong bottom-line traction and may imply robust demand in key geographies and better utilization of manufacturing capacities. No information is available in the given context on street expectations, consensus forecasts, or specific margin metrics, so any comparison with analyst estimates is not attempted. Similarly, there is no verified data in the context on immediate stock price reaction on the NSE or BSE to these Q1 numbers, and hence market reaction is not discussed.
Given the substantial year-on-year increase in consolidated net profit, the results would generally be viewed as operationally supportive for the company’s near-term earnings trajectory, especially within the broader Indian pharmaceutical sector. However, without granular disclosures on revenue growth, segment performance, or management guidance, the summary remains constrained to the confirmed profit figures and their year-on-year change.

